An Open-label Study of Nelotanserin in Patients With Lewy Body Dementia Who Have Frequent Visual Hallucinations or REM Sleep Behavior Disorder

Trial Profile

An Open-label Study of Nelotanserin in Patients With Lewy Body Dementia Who Have Frequent Visual Hallucinations or REM Sleep Behavior Disorder

Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Feb 2018

At a glance

  • Drugs Nelotanserin (Primary)
  • Indications Lewy body disease
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Axovant Sciences
  • Most Recent Events

    • 13 Feb 2018 Planned End Date changed from 1 Jul 2018 to 1 Jul 2019.
    • 13 Feb 2018 Planned primary completion date changed from 1 Jul 2018 to 1 Jul 2019.
    • 07 Aug 2017 According to a Axovant media release, the company anticipates top-line results in the first quarter 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top